Answers are grounded in this paper and cite their sources.
The promising efficacy signal suggests selinexor has potential as a maintenance therapy for TP53wt EC to address current treatment gaps. A phase 3 study is currently enrolling to further evaluate its role in patients with advanced/recurrent EC.
No takes yet. Share an insight, caveat, or question.
Coleman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: